Interestingly, in a stratified survival analysis using this cut-off (cut-off-Q4), we found that the impact of DSC2 on overall survival (not shown) and disease-free survival was limited to the group of TNBC and HER2-positive patients (p = 0.0016 and p = 0.004, respectively; Fig. 1D), whereas in patients with luminal breast cancer the DSC2 level did not influence the survival time. This evidence concerns the gene DSC2 and breast cancer.